These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28665676)

  • 1. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
    Mantravadi S
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
    [No Abstract]   [Full Text] [Related]  

  • 2.  The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico.
    Méndez-Sánchez N
    Ann Hepatol; 2012; 11(4):550-1. PubMed ID: 22700637
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
    Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
    BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Burden of Hepatitis C Infection.
    Stepanova M; Younossi ZM
    Clin Liver Dis; 2017 Aug; 21(3):579-594. PubMed ID: 28689595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma.
    Hoshida Y; Shiratori Y; Omata M
    Liver; 2002 Dec; 22(6):479-85. PubMed ID: 12445173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
    Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
    CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource use and cost of hepatitis C-related care.
    Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges.
    Soriano V; Tefferi A
    Cancer; 2018 Apr; 124(8):1647-1649. PubMed ID: 29486060
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
    Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
    Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatitis B and hepatitis C, a high stake for public health: how to reconcile health cost control and public health expenses?].
    Allerg Immunol (Paris); 1997 Sep; 29(7):215-8. PubMed ID: 9432191
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus.
    Valla DC; Degos F
    J Hepatol; 2001 Apr; 34(4):606-9. PubMed ID: 11394663
    [No Abstract]   [Full Text] [Related]  

  • 13. Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma.
    Saab S; Jimenez M; Fong T; Wu C; El Kabany M; Tong MJ
    Exp Clin Transplant; 2016 Feb; 14(1):66-71. PubMed ID: 26581477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
    Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma.
    Brechot C
    Hepatology; 1997 Mar; 25(3):772-4. PubMed ID: 9049234
    [No Abstract]   [Full Text] [Related]  

  • 19. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.